S&P 500   4,509.15 (-1.48%)
DOW   34,358.06 (-0.81%)
QQQ   380.19 (-2.49%)
AAPL   160.14 (-2.21%)
MSFT   320.00 (-2.88%)
FB   304.22 (-1.99%)
GOOGL   2,817.11 (-1.48%)
AMZN   3,357.83 (-2.31%)
TSLA   1,013.85 (-6.52%)
NVDA   303.15 (-5.64%)
BABA   112.32 (-7.93%)
NIO   31.87 (-11.96%)
CGC   9.92 (-4.25%)
AMD   141.88 (-5.84%)
GE   91.95 (-3.44%)
MU   80.99 (-2.28%)
T   23.40 (+1.52%)
F   19.00 (-4.38%)
DIS   144.58 (-1.78%)
PFE   54.12 (+2.04%)
AMC   26.17 (-13.57%)
ACB   5.75 (-6.35%)
BA   195.90 (-3.20%)
S&P 500   4,509.15 (-1.48%)
DOW   34,358.06 (-0.81%)
QQQ   380.19 (-2.49%)
AAPL   160.14 (-2.21%)
MSFT   320.00 (-2.88%)
FB   304.22 (-1.99%)
GOOGL   2,817.11 (-1.48%)
AMZN   3,357.83 (-2.31%)
TSLA   1,013.85 (-6.52%)
NVDA   303.15 (-5.64%)
BABA   112.32 (-7.93%)
NIO   31.87 (-11.96%)
CGC   9.92 (-4.25%)
AMD   141.88 (-5.84%)
GE   91.95 (-3.44%)
MU   80.99 (-2.28%)
T   23.40 (+1.52%)
F   19.00 (-4.38%)
DIS   144.58 (-1.78%)
PFE   54.12 (+2.04%)
AMC   26.17 (-13.57%)
ACB   5.75 (-6.35%)
BA   195.90 (-3.20%)
S&P 500   4,509.15 (-1.48%)
DOW   34,358.06 (-0.81%)
QQQ   380.19 (-2.49%)
AAPL   160.14 (-2.21%)
MSFT   320.00 (-2.88%)
FB   304.22 (-1.99%)
GOOGL   2,817.11 (-1.48%)
AMZN   3,357.83 (-2.31%)
TSLA   1,013.85 (-6.52%)
NVDA   303.15 (-5.64%)
BABA   112.32 (-7.93%)
NIO   31.87 (-11.96%)
CGC   9.92 (-4.25%)
AMD   141.88 (-5.84%)
GE   91.95 (-3.44%)
MU   80.99 (-2.28%)
T   23.40 (+1.52%)
F   19.00 (-4.38%)
DIS   144.58 (-1.78%)
PFE   54.12 (+2.04%)
AMC   26.17 (-13.57%)
ACB   5.75 (-6.35%)
BA   195.90 (-3.20%)
S&P 500   4,509.15 (-1.48%)
DOW   34,358.06 (-0.81%)
QQQ   380.19 (-2.49%)
AAPL   160.14 (-2.21%)
MSFT   320.00 (-2.88%)
FB   304.22 (-1.99%)
GOOGL   2,817.11 (-1.48%)
AMZN   3,357.83 (-2.31%)
TSLA   1,013.85 (-6.52%)
NVDA   303.15 (-5.64%)
BABA   112.32 (-7.93%)
NIO   31.87 (-11.96%)
CGC   9.92 (-4.25%)
AMD   141.88 (-5.84%)
GE   91.95 (-3.44%)
MU   80.99 (-2.28%)
T   23.40 (+1.52%)
F   19.00 (-4.38%)
DIS   144.58 (-1.78%)
PFE   54.12 (+2.04%)
AMC   26.17 (-13.57%)
ACB   5.75 (-6.35%)
BA   195.90 (-3.20%)
NASDAQ:CLSN

Celsion Stock Forecast, Price & News

$0.69
-0.03 (-3.50%)
(As of 12/3/2021 01:52 PM ET)
Add
Compare
Today's Range
$0.68
$0.70
50-Day Range
$0.71
$1.05
52-Week Range
$0.57
$3.48
Volume
7,867 shs
Average Volume
6.32 million shs
Market Capitalization
$59.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.88
30 days | 90 days | 365 days | Advanced Chart
Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for Celsion and its competitors with MarketBeat's FREE daily newsletter.


Celsion logo

About Celsion

Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Headlines

Celsion Co. (NASDAQ:CLSN) Short Interest Down 27.1% in November
December 2, 2021 |  americanbankingnews.com
CLSN: OVATION 2 Trial Nears 70% of Target Enrollment…
November 17, 2021 |  finance.yahoo.com
Celsion (NASDAQ:CLSN) Announces Earnings Results
November 16, 2021 |  americanbankingnews.com
Brokerages Expect Celsion Co. (NASDAQ:CLSN) to Post -$0.08 EPS
November 15, 2021 |  americanbankingnews.com
Celsion (CLSN) Set to Announce Earnings on Monday
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSN
Employees
27
Year Founded
1982

Sales & Book Value

Annual Sales
$500 thousand
Book Value
$0.46 per share

Profitability

Net Income
$-21.48 million
Net Margins
-3,912.20%
Pretax Margin
-4,281.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
83,130,000
Market Cap
$59.73 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/18/2022

Social Links


MarketRank

Overall MarketRank

1.27 out of 5 stars

Medical Sector

1174th out of 1,391 stocks

Pharmaceutical Preparations Industry

560th out of 669 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Celsion (NASDAQ:CLSN) Frequently Asked Questions

Is Celsion a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Celsion stock.
View analyst ratings for Celsion
or view top-rated stocks.

How has Celsion's stock been impacted by COVID-19 (Coronavirus)?

Celsion's stock was trading at $0.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLSN stock has decreased by 30.3% and is now trading at $0.69.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Celsion?

Celsion saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,720,000 shares, a decrease of 27.1% from the October 31st total of 2,360,000 shares. Based on an average daily trading volume, of 961,300 shares, the days-to-cover ratio is currently 1.8 days.
View Celsion's Short Interest
.

When is Celsion's next earnings date?

Celsion is scheduled to release its next quarterly earnings announcement on Friday, March 18th 2022.
View our earnings forecast for Celsion
.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. Celsion had a negative trailing twelve-month return on equity of 39.72% and a negative net margin of 3,912.20%. During the same quarter in the previous year, the business posted ($0.17) EPS.
View Celsion's earnings history
.

When did Celsion's stock split? How did Celsion's stock split work?

Celsion shares reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

Who are Celsion's key executives?

Celsion's management team includes the following people:
  • Michael H. Tardugno, Chairman, President & Chief Executive Officer
  • Jeffrey Wayne Church, CFO, Secretary & SVP-Investor Relations
  • Nicholas Borys, Chief Medical Officer & Senior Vice President
  • Khursheed Anwer, Chief Scientific Officer & Executive VP
  • Jason G. Fewell, Vice President-Preclinical Research

What other stocks do shareholders of Celsion own?

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Who are Celsion's major shareholders?

Celsion's stock is owned by many different institutional and retail investors. Top institutional shareholders include Morgan Stanley (2.69%), BlackRock Inc. (1.27%), Geode Capital Management LLC (0.87%), Two Sigma Advisers LP (0.08%), Two Sigma Investments LP (0.06%) and Jane Street Group LLC (0.04%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Donald P Braun, Donald P Braun and Frederick J Fritz.
View institutional ownership trends for Celsion
.

Which major investors are selling Celsion stock?

CLSN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, BlackRock Inc., and Citadel Advisors LLC.
View insider buying and selling activity for Celsion
or view top insider-selling stocks.

Which major investors are buying Celsion stock?

CLSN stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Advisers LP, Geode Capital Management LLC, and Jane Street Group LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Donald P Braun, and Frederick J Fritz.
View insider buying and selling activity for Celsion
or or view top insider-buying stocks.

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $0.69.

How much money does Celsion make?

Celsion has a market capitalization of $59.73 million and generates $500 thousand in revenue each year. The biotechnology company earns $-21.48 million in net income (profit) each year or ($0.26) on an earnings per share basis.

How many employees does Celsion have?

Celsion employs 27 workers across the globe.

When was Celsion founded?

Celsion was founded in 1982.

What is Celsion's official website?

The official website for Celsion is www.celsion.com.

Where are Celsion's headquarters?

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at (609) 896-9100, via email at [email protected], or via fax at 609-896-2200.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.